Recently, there is a growing interest in the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the treatment of AHF, as these drugs have shown promising results in improving cardiovascular outcomes in patients with heart failure (HF) across the entire range of ejection fraction (EF) [3–5]. The gene discussed is SLC5A2; the disease is heart failure.